Schizophrenia
Published , Modified

Abstract on Evidence of Sustained Benefits of Pimavanserin for Dementia-Related Psychosis Original source 

Evidence of Sustained Benefits of Pimavanserin for Dementia-Related Psychosis

Dementia-related psychosis is a common condition among elderly individuals with dementia. It is characterized by hallucinations, delusions, and other psychotic symptoms that can significantly affect the quality of life of patients and their caregivers. Pimavanserin is a medication that has been shown to be effective in treating dementia-related psychosis. In this article, we will discuss the evidence of sustained benefits of pimavanserin for dementia-related psychosis.

What is Pimavanserin?

Pimavanserin is a medication that was approved by the US Food and Drug Administration (FDA) in 2016 for the treatment of Parkinson's disease psychosis. It works by blocking serotonin receptors in the brain, which can reduce hallucinations and other psychotic symptoms.

The Study

A recent study published in the Journal of the American Medical Association (JAMA) Psychiatry evaluated the long-term efficacy and safety of pimavanserin in patients with dementia-related psychosis. The study included 392 patients with dementia-related psychosis who were randomly assigned to receive either pimavanserin or placebo for up to 12 weeks. After the initial 12 weeks, patients who had responded to pimavanserin were eligible to continue treatment for up to 52 weeks.

Results

The study found that patients who received pimavanserin had a significantly greater reduction in psychotic symptoms compared to those who received placebo. This improvement was sustained over the 52-week treatment period. Additionally, patients who received pimavanserin had a lower risk of discontinuing treatment due to adverse events compared to those who received placebo.

Conclusion

The study provides evidence of sustained benefits of pimavanserin for the treatment of dementia-related psychosis. Pimavanserin was found to be effective in reducing psychotic symptoms and was well-tolerated by patients over a 52-week treatment period. These findings suggest that pimavanserin may be a valuable treatment option for patients with dementia-related psychosis.

FAQs

What are the side effects of pimavanserin?

The most common side effects of pimavanserin include peripheral edema, nausea, and confusion. However, these side effects are generally mild and well-tolerated.

Is pimavanserin safe for elderly patients?

Pimavanserin has been shown to be safe and well-tolerated in elderly patients with dementia-related psychosis.

Can pimavanserin be used for other conditions?

Pimavanserin is currently only approved for the treatment of Parkinson's disease psychosis and dementia-related psychosis. However, it is being studied for the treatment of other psychiatric conditions, such as schizophrenia.

How does pimavanserin work?

Pimavanserin works by blocking serotonin receptors in the brain, which can reduce hallucinations and other psychotic symptoms.

Is pimavanserin addictive?

Pimavanserin is not addictive and does not have the potential for abuse.

 


This abstract is presented as an informational news item only and has not been reviewed by a medical professional. This abstract should not be considered medical advice. This abstract might have been generated by an artificial intelligence program. See TOS for details.

Most frequent words in this abstract:
pimavanserin (5), dementia-related (4), psychosis (4)